Showing 828 results
-
Story /Novartis's annual mentoring program inspires over 100 students to shape the future of healthcare, offering direct interaction with industry leaders.
-
Media Release /Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive…
-
Media Release /Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to…
-
Media Release /Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories" offers an intimate look into the journeys of six individuals living with…
-
Media Release /Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-–C) reduction beyond six…
-
Media Release /With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in…
